Lilly extends decline post RFK Jr's nomination for US health job
** Shares of drugmaker Eli Lilly LLY.N fall ~3.8% to $718.08, its fifth straight session of losses
** BMO Capital Markets analyst Evan Seigerman says Lilly's shares have fallen because of follow through from Thursday's announcement of Robert F. Kennedy Jr's nomination as head of the U.S. Department of Health and Human Services
** Shares of obesity drugmakers such as Novo Nordisk NOVOb.CO, NVO.O and Lilly have been falling since the decision
** Kennedy criticizes that these obesity drugs focuses on symptoms rather than improving the food system
** Seigerman says Kennedy remains limited in his ability to influence either policy or pricing of obesity medications
** Lilly's shares had been up 55% so far until October, making it the world's most valuable healthcare company
** Separately, Novo says it launched its popular obesity drug Wegovy in China
** However, the U.S.-listed shares of the drugmaker are down 1.5% at $100.20
** Up to last close, LLY stock up 23.9%, NVO down 3% YTD
Reporting by Christy Santhosh
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
